Table 3. Subgroup analyses relating to the diagnostic odds ratio (DOR) of first-pass CTA for hematoma expansion.

Subgroups	Hematoma expansion
	Studies, n	DOR (95% CI)	I2, %
Study design
Prospective	8	10.94 (6.58–18.19)	58.0
Retrospective	6	12.79 (4.70–34.79)	82.6
Sample size
≥100	11	10.41 (6.28–17.27)	75.2
<100	3	26.92 (9.44–76.74)	0
Blinded assessment
Yes	8	8.91 (5.76–13.80)	51.1
None/Unknown	6	17.56 (6.25–49.36)	79.8